Peichl, Peter http://orcid.org/0000-0002-1090-7904
Alten, Rieke
Galeazzi, Mauro
Lorenz, Hanns-Martin
Nüßlein, Hubert
Navarro, Federico
Elbez, Yedid
Chartier, Melanie
Hackl, Roland
Rauch, Christiane
Connolly, Sean E
Article History
Received: 27 March 2019
Accepted: 20 September 2019
First Online: 25 October 2019
Compliance with Ethical Guidelines
:
: M. Galeazzi declares that he has no competing interests. P. Peichl: consulting fees: Astropharma, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sandoz; research grants: Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis. R. Alten: research grants: Bristol-Myers Squibb. H.-M. Lorenz: consulting fees: AbbVie, Actelion, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Janssen-Cilag, Medac, Merck Sharp & Dohme, Novartis, Pfizer, Roche-Chugai, Sobi, UCB. H. Nüßlein: consulting fees: AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, UCB. F. Navarro: consulting fees: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, Roche, UCB; research grants: AbbVie, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, Roche; speakers’ bureau: AbbVie, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, Roche, UCB. Y. Elbez: consulting fees: Bristol-Myers Squibb. M. Chartier, R. Hackl: employment: Bristol-Myers Squibb. C. Rauch, S.E. Connolly: employment and shareholding: Bristol-Myers Squibb.
: ACTION was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization Good Clinical Practice guidelines, and the Good Epidemiological Practice guidelines. The study protocol and patient enrollment materials were approved by local ethics committees and review boards. All enrolled patients provided written informed consent in accordance with local laws.